RxDoctor Payments Data

Gloria Heresi

Pediatric Infectious Diseases · Houston, TXNPI 1689618050

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $21,129 of the $21,927 with a category attached, or 96.4%. Gilead accounts for 97.5% of it on its own, with 7 other manufacturers making up the rest.

$21,927in general payments, 2019–2025

Across 112 payments — averaging $195.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$21K
  • Merck$214
  • Astellas Pharma US Inc$121
  • Melinta Therapeutics, LLC$93
  • Tetraphase Pharmaceuticals, Inc.$57
  • Pfizer$28
  • plus $36 from 2 others
$388,249in research payments, 2019–2025

Across 91 payments — averaging $4266.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$149K
  • Viiv Healthcare Company$93K
  • Paratek Pharmaceuticals, Inc.$62K
  • Hoffmann-la Roche Limited$42K
  • AstraZeneca$23K
  • Gilead$19K
  • plus $340 from 1 others

What the payments were for

  • Consulting fees$21,12996%
  • Travel & lodging$70%
  • Food & beverage$7623%
  • Education$290%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$21,927 in reported general payments places this provider in the 85th percentile of 66 pediatric infectious diseases providers in Texas.

See all pediatric infectious diseases providers in Texas →

Other pediatric infectious diseases in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →